Trygg Pharma, Inc., a subsidiary of Aker BioMarine, Oslo, Norway, is currently enrolling patients in its clinical trial, a Phase III clinical study assessing the efficacy of AKR 963—an investigational candidate drug developed by the company—for treating patients with severe hypertriglyceridemia.